3 1 lundbeck-3.txt FORM 3 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 ________________________________________________________________________________ 1. Name and Address of Reporting Person* H. Lundbeck A/S -------------------------------------------------------------------------------- (Last) (First) (Middle) 9 Ottiliavej, DK-2500 Valby -------------------------------------------------------------------------------- (Street) Copenhagen, Denmark -------------------------------------------------------------------------------- (City) (State) (Zip) ________________________________________________________________________________ 2. Date of Event Requiring Statement (Month/Day/Year) 11/21/02 ________________________________________________________________________________ 3. IRS Identification Number of Reporting Person, if an Entity (Voluntary) ________________________________________________________________________________ 4. Issuer Name and Ticker or Trading Symbol Synaptic Pharmaceutical Corporation (NASDAQ:SNAP) ________________________________________________________________________________ 5. Relationship of Reporting Person to Issuer (Check all applicable) [_] Director [x] 10% Owner [_] Officer (give title below) [_] Other (specify below) ________________________________________________________________________________ 6. If Amendment, Date of Original (Month/Day/Year) ________________________________________________________________________________ 7. Individual or Joint/Group Filing (Check applicable line) [x] Form Filed by One Reporting Person [_] Form Filed by More than One Reporting Person ================================================================================ Table I -- Non-Derivative Securities Beneficially Owned ================================================================================
3. Ownership Form: 2. Amount of Securities Direct (D) or 1. Title of Security Beneficially Owned Indirect (I) 4. Nature of Indirect Beneficial Ownership (Instr. 4) (Instr. 4) (Instr. 5) (Instr. 5) ------------------------------------------------------------------------------------------------------------------------------------ Common Stock, par value $0.01 0 per share (1) ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ ====================================================================================================================================
* If the Form is filed by more than one Reporting Person, see Instruction 5(b)(v). Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. (Print of Type Responses) (Over) FORM 3 (continued) Table II -- Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) ================================================================================
5. Owner- 3. Title and Amount of Securities ship Underlying Derivative Security Form of 2. Date Exercisable (Instr. 4) Derivative and Expiration Date --------------------------------- 4. Conver- Security: (Month/Day/Year) Amount sion or Direct 6. Nature of ---------------------- or Exercise (D) or Indirect Date Expira- Number Price of Indirect Beneficial 1. Title of Derivative Exer- tion of Derivative (I) Ownership Security (Instr. 4) cisable Date Title Shares Security (Instr. 5) (Instr. 5) ------------------------------------------------------------------------------------------------------------------------------------ Series B Convertible Exercisable (2) Common Stock, par 0 (3) $4.3358 Preferred Stock, immediately value $0.01 per share par value $0.01 per share (1) ------------------------------------------------------------------------------------------------------------------------------------ Series C Convertible Exercisable (2) Common Stock, par 0 (3) $5.9713 Preferred Stock, immediately value $0.01 per share par value $0.01 per share (1) ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ ==================================================================================================================================== Explanation of Responses: (1) In connection with the Agreement and Plan of Merger dated as of November 21, 2002 (the "Merger Agreement"), among H. Lundbeck A/S ("Lundbeck"), Viking Sub Corporation and Synaptic Pharmaceutical Corporation ("Synaptic"), Lundbeck entered into a Stockholder Agreement dated as of November 21, 2002 (the "Stockholder Agreement"), with Warburg Pincus Private Equity VIII, L.P. ("Warburg Pincus"). Under the terms of the Stockholder Agreement, Warburg Pincus has agreed to vote all of its 9,398 shares of Synaptic Series B Convertible Preferred Stock (the "Series B Preferred Stock") and 25,452 shares of Synaptic Series C Convertible Preferred Stock (the "Series C Preferred Stock" and, together with the Series B Preferred Stock, the "Synaptic Preferred Stock") in favor of the Merger Agreement and against any competing transactions. In addition, Warburg Pincus has granted Lundbeck an irrevocable proxy to vote the Synaptic Preferred Stock in accordance with the Stockholder Agreement. The Stockholder Agreement terminates upon the earlier of (i) the effective time of the merger contemplated by the Merger Agreement and (ii) the termination of the Merger Agreement in accordance with its terms. The Stockholder Agreement is filed as Exhibit 1 to the Schedule 13D/A filed pursuant to the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"), by Warburg Pincus on November 22, 2002 (file no. 005-45417), and is incorporated herein by reference. The Merger Agreement is filed as Exhibit 2.1 to the Form 8-K filed by Synaptic pursuant to the Securities Exchange Act on November 21, 2002 (file no. 000-27324), and is incorporated herein by reference. Because the Synaptic Preferred Stock is convertible into 6,429,923 shares of common stock, par value $.01 per share (NASDAQ: SNAP) (the "Common Stock"), for purposes of calculating ten percent beneficial ownership, Lundbeck is deemed to "beneficially own" (as defined in Rule 16a-1(a)(1) promulgated under the Securities Exchange Act) 6,429,923 shares of Common Stock, 9,398 shares of Series B Preferred Stock and 25,452 shares of Series C Preferred Stock. However, for purposes of disclosing securities holdings on this Form 3, Lundbeck does not "beneficially own" (as defined in Rule 16a-1(a)(2) promulgated under the Securities Exchange Act) any equity security of Synaptic. (2) The Synaptic Preferred Stock is subject to mandatory redemption as follows: (i) on August 3, 2009, Synaptic shall redeem fifty percent (50%) of Synaptic Preferred Stock outstanding on such date, and (ii) on August 3, 2010, Synaptic shall redeem all shares of Synaptic Preferred Stock which remain outstanding as of such date. (3) The Series B Preferred Stock is convertible into 2,167,535 shares of Common Stock and the Series C Preferred Stock is convertible into 4,262,388 shares of Common Stock. **Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
/s/ Hans Henrik Munch-Jensen November 27th, 2002 --------------------------------------------- ----------------------- Name: Hans Henrik Munch-Jensen Date Title: Senior Vice President - CFO **Signature of Reporting Person Note: File three copies of this form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.